Cassava Sciences Files 8-K on Financial Condition
Ticker: FLNA · Form: 8-K · Filed: Feb 28, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Feb 28, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**Cassava Sciences just dropped an 8-K on their financials, so keep an eye out for details on their performance.**
AI Summary
Cassava Sciences, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates that the company, based in Austin, Texas, with IRS Employer Identification No. 91-1911336, is a pharmaceutical preparations company. This current report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on Cassava Sciences' financial health and operational performance, which is crucial for investors to assess the company's stability and future prospects in the pharmaceutical industry.
Risk Assessment
Risk Level: medium — The filing itself is a standard disclosure of financial condition and does not inherently indicate a high or low risk without further details on the actual financial results.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- Austin, Texas (location) — Principal Executive Offices
- 91-1911336 (number) — I.R.S. Employer Identification No.
- Delaware (location) — State of Incorporation
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 28, 2024.
What is the primary business address of Cassava Sciences, Inc.?
The primary business address is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
Under which sections of the Securities Exchange Act of 1934 was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the IRS Employer Identification No. for Cassava Sciences, Inc.?
The IRS Employer Identification No. is 91-1911336.
What items of information were included in this 8-K filing?
The item information included 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-02-28 09:22:12
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- f8k_022824.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 78KB
- 0001171843-24-001035.txt ( ) — 299KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_022824_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 28, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated February 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. Date: February 28, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer